Clinical Trial Results: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate [Phase 3]

View source ↗

Summary

Phase 3 randomized study evaluating MACE in prostate cancer patients treated with relugolix versus leuprolide acetate completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprolide acetate (Leuprolide acetate)
• Relugolix (Relugolix)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2026-06-15